Grant Jennifer M, Porter Charlene, Charles Marthe K, Bryce Elizabeth A, Wong Titus, Stefanovic Aleksandra, Shajari Salomeh, Roscoe Diane L
Department of Pathology and Laboratory Medicine, Vancouver General Hospital, Vancouver, British Columbia, Canada.
Department of Pathology and Laboratory Medicine, Vancouver Costal Health Authority, Vancouver, British Columbia, Canada.
J Assoc Med Microbiol Infect Dis Can. 2020 Mar 4;5(1):21-28. doi: 10.3138/jammi.2019-0002. eCollection 2020 Mar.
The Accelerate Pheno system (AXDX) provides rapid identification (ID; 90 minutes) and antimicrobial susceptibility testing (AST; approximately 7 hours) from positive blood culture (BC) bottles. We assessed the potential of AXDX results to influence more timely antibiotic interventions with a convenience sample of 158 positive BCs.
BCs with a mono-microbial Gram stain likely to be on the AXDX panel were run in parallel with the standard of care (SOC). Using results from the SOC, the medical microbiologist on call (MMOC) noted interventions made at the time of BC Gram stain and when ID and AST results were available. The timing of MMOC intervention was noted and compared with fastest potential SOC time and AXDX time.
Of 158 specimens selected for analysis, 144 were evaluable. ID was available 11.9 hours and AST 27.7 hours faster than SOC. Correct ID was provided for 85.2% of specimens and AST for 59.0% of specimens, with 97.5% essential agreement compared with the SOC. One hundred and thirteen clinical interventions were made on 100 specimens: 54.9% were narrowing; 33.6%, escalation; 6.2%, consultation with ID; and 3.5%, further investigation. If AXDX data had been used immediately once available, interventions would have been possible 24 hours earlier for ID interventions and 39 hours earlier for AST results.
Results from rapid diagnostic panels such as AXDX have the potential to support timely antimicrobial de-escalation and other decisions to benefit patients, especially if paired with stewardship interventions.
加速 Pheno 系统(AXDX)可对阳性血培养瓶进行快速鉴定(90 分钟)和抗菌药物敏感性测试(约 7 小时)。我们通过 158 份阳性血培养的便利样本评估了 AXDX 结果对更及时的抗生素干预的潜在影响。
对革兰氏染色显示为单一微生物且可能在 AXDX 检测范围内的血培养样本,与标准治疗方法(SOC)并行检测。根据 SOC 的结果,值班医学微生物学家记录在血培养革兰氏染色时以及获得鉴定和药敏结果时所采取的干预措施。记录值班医学微生物学家干预的时间,并与最快的潜在 SOC 时间和 AXDX 时间进行比较。
在选取用于分析的 158 份样本中,144 份可评估。鉴定结果比 SOC 快 11.9 小时,药敏结果快 27.7 小时。85.2%的样本提供了正确的鉴定结果,59.0%的样本提供了药敏结果,与 SOC 相比基本一致率为 97.5%。对 100 份样本进行了 113 次临床干预:54.9%为缩小抗菌谱;33.6%为升级抗菌治疗;6.2%为咨询感染病专家;3.5%为进一步调查。如果 AXDX 数据一经获得便立即使用,那么对于鉴定结果的干预可能提前 24 小时进行,对于药敏结果的干预可能提前 39 小时进行。
AXDX 等快速诊断平台的结果有可能支持及时的抗菌药物降阶梯治疗及其他有利于患者的决策,特别是与管理干预措施相结合时。